Vertex Pharmaceuticals (VRTX) Other Non-Current Liabilities (2009 - 2026)

Vertex Pharmaceuticals has reported Other Non-Current Liabilities for 18 years, with the latest figure at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 31.88% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 31.88% YoY), and the FY2025 full-year result was $1.3 billion, up 25.12% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $1.3 billion, down from $1.3 billion in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $1.3 billion in Q4 2025, with the low at $127.2 million in Q3 2022.
• Average Other Non-Current Liabilities over 5 years is $819.9 million, with a median of $876.8 million recorded in 2024.
• Year-over-year, Other Non-Current Liabilities sank 30.7% in 2022 and soared 583.41% in 2023.
• Tracing VRTX's Other Non-Current Liabilities over 5 years: stood at $685.8 million in 2022, then increased by 27.98% to $877.7 million in 2023, then increased by 15.6% to $1.0 billion in 2024, then grew by 25.12% to $1.3 billion in 2025, then decreased by 1.11% to $1.3 billion in 2026.
• The last three Other Non-Current Liabilities figures came in at $1.3 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.

Peer Comparison